In this post
Optellum, the leader in AI-enabled lung cancer diagnostics, today announced that its Virtual Nodule Clinic (VNC) with Lung Cancer Prediction (LCP) AI is integrated with the Rapid Enterprise™ Platform from RapidAI, a global leader in enterprise clinical AI. VNC joins a portfolio of 50+ RapidAI-developed and third-party clinical solutions that support radiologists and care teams across the patient journey, extending the platform's oncology coverage to the lung nodule pathway. RapidAI technology is used in more than 2,500 hospitals across 100+ countries.
Lung cancer remains the leading cause of cancer death in the United States and worldwide.1 Many lung nodules are found incidentally on CT scans performed for other reasons, and 60% are lost to follow-up2. Without a clear path to follow-up, the opportunity for earlier diagnosis can be missed.
Optellum VNC includes Patient Discovery AI, which automatically searches radiology reports for documented lung nodules and identifies patients for review. VNC’s workflow management tools support patient tracking and follow-up, and LCP AI analyzes CT images to assess a nodule's cancer risk. Together, these capabilities help care teams prioritize patients and reduce the risk of patients being lost to follow-up. VNC with LCP AI is the world's first FDA-cleared and Medicare-reimbursed AI solution for image-based lung cancer risk stratification, reimbursed under named CPT 0721T/+0722T.
Optellum is directly deployed at hundreds of clinical sites and has analyzed over 3 million cases to date. Integration with the Rapid Enterprise Platform will help accelerate that footprint, bringing Optellum’s capabilities to more care teams.
Through the integration, pulmonologists and clinic managers can access Optellum's capabilities as part of a connected enterprise platform. Health systems can deploy Optellum on their existing RapidAI platform through a single IT deployment, supported by consistent clinical workflows, best-in-class clinical solutions, and shared AI governance capabilities that provide a central place to monitor performance and oversee AI use.
"Our collaboration with RapidAI makes Virtual Nodule Clinic available to the many health systems that already rely on the Rapid Enterprise Platform," said Johnathan Watkins, PhD, CEO of Optellum. "Integrating VNC into the Rapid platform expands access, streamlines IT deployment, and accelerates putting clinically validated solutions in the hands of care teams. Together, we can help more patients with lung nodules get the right care sooner."
The solutions support clinical decision-making, with qualified clinicians responsible for interpreting results and determining appropriate patient care.
About RapidAI
RapidAI is a global leader in enterprise clinical AI, trusted by more than 2,500 hospitals across 100+ countries and backed by 800+ clinical studies. The Rapid Enterprise™ Platform combines 50+ RapidAI-developed and third-party algorithms spanning neurology, cardiac and vascular, trauma, and oncology care. Paired with enterprise workflow solutions that connect radiology and clinical teams throughout the patient journey, it turns imaging and patient data into actionable clinical context, moving radiologists and clinicians from detection to confident action. Powered by Rapid Edge Cloud and built to integrate with existing workflows and health IT systems, it helps health systems reduce fragmentation, improve collaboration, and deliver faster, more consistent care across the enterprise.
For more information, visit rapidai.com.
About Optellum
Optellum is a commercial-stage AI healthcare company dedicated to revolutionizing early diagnosis and treatment of lung disease, starting with one of the deadliest, lung cancer.
Optellum is building LungOS®, the end-to-end AI-powered platform for thoracic care. Its flagship product, Virtual Nodule Clinic (VNC) with Lung Cancer Prediction (LCP) AI, is the world's first FDA-cleared and reimbursed software-as-a-medical-device (SaMD) solution for AI-powered lung cancer prioritization and diagnostic support. Clinicians trust the Optellum solution to aid them in making the most appropriate life-saving treatment decisions for their patients. Backed by real-world clinical evidence, Optellum's solution accelerates the diagnostic care pathway by enabling early patient identification, enhancing prioritization, and improving clinicians' efficiency, reducing time to guideline-recommended treatment. Optellum VNC is commercially available in USA, EU/EEA, UK, Switzerland and Australia.
Optellum is headquartered in Oxford, UK, and has an office in Houston, Texas, US.
For more information, visit optellum.com.
References: 1. World Health Organization, International Agency for Research on Cancer (IARC), Global Cancer Observatory. 2. Pyenson et al 2019
Media Contact:
